Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States and internationally. Its Branded Pharmaceuticals segment provides branded prescription products, including XIAFLEX to treat adult patients with Dupuytren's contracture; SUPPRELIN LA to treat central precocious puberty in children; NASCOBAL nasal spray to treat vitamin B12 deficiency; AVEED to treat hypogonadism; QWO, an injectable treatment for moderate to severe cellulite in the buttocks of adult women; PERCOCET to treat moderate-to-moderately-severe pain; TESTOPEL an implantable pellet indicated for TRT in conditions associated with a deficiency or absence of endogenous testosterone; EDEX to treat erectile dysfunction; LIDODERM a topical patch product containing lidocaine for the relief of pain; and products for the pain management and urology. The company's Sterile Injectables segment manufactures VASOSTRICT, a vasopressin injection; ADRENALIN, a non-selective adrenergic agonist; and APLISOL, which is a sterile aqueous solution, as well as generic sterile injectable products, including ertapenem for injections and ephedrine sulfate injections. Its Generic Pharmaceuticals segment offers solid oral extended-release, solid oral immediate-release, liquids, semi-solids, patches, powders, ophthalmic products, and sprays. The company's International Pharmaceuticals segment offers specialty pharmaceutical products in various therapeutic areas comprising attention deficit hyperactivity disorder, pain, women's health, oncology, and transplantation. The company sells its branded pharmaceuticals and generics to specialty physicians, retailers, clinics, government agencies, doctors, retail and specialty pharmacies, and specialty distributors. Endo International plc was founded in 1920 and is headquartered in Dublin, Ireland. On August 16, 2022, Endo International plc, along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of New York.
Show more...
CEO
Blaise Coleman
Mitarbeiter
2931
Land
IE
ISIN
IE00BJ3V9050
WKN
000A1XE6M
Listings
0 Comments
Teile deine Gedanken
FAQ
Wie ist der Aktienkurs von Endo International heute?▼
Der aktuelle Preis von ENDPQ beträgt $0 USD — er ist in den letzten 24 Stunden um +0% gestiegen. Verfolge die Kursentwicklung von Endo International genauer im Chart.
Was ist das Endo International-Aktien-Symbol?▼
Je nach Börse kann das Aktiensymbol variieren. Zum Beispiel werden Endo International-Aktien an der Börse unter dem Symbol ENDPQ gehandelt.
Wie hoch war der Umsatz von Endo International im letzten Jahr?▼
Der Umsatz von Endo International im letzten Jahr beträgt 2.01B USD.
Wie hoch war der Nettogewinn von Endo International im letzten Jahr?▼
Der Nettogewinn von ENDPQ im letzten Jahr beträgt -2.45B USD.
Wie viele Mitarbeiter hat Endo International?▼
Stand April 01, 2026 hat das Unternehmen 2,931 Mitarbeitende.
In welchem Sektor ist Endo International tätig?▼
Endo International ist im Sektor Professional, Scientific, and Technical Services tätig.
Wann hat Endo International einen Split durchgeführt?▼
Endo International hatte in letzter Zeit keine Splits.
Wo hat Endo International seinen Hauptsitz?▼
Der Hauptsitz von Endo International befindet sich in Dublin, IE.